Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status - Aix-Marseille Université Access content directly
Journal Articles Anti-Cancer Drugs Year : 2009

Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status

Domains

Cancer
No file

Dates and versions

hal-03623811 , version 1 (29-03-2022)

Identifiers

Cite

Anthony Gonçalves, Mathilde Deblock, Benjamin Esterni, Carole Tarpin, François Bertucci, et al.. Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status. Anti-Cancer Drugs, 2009, 20 (10), pp.946-952. ⟨10.1097/cad.0b013e328331178f⟩. ⟨hal-03623811⟩
10 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More